By Mill Chart
Last update: Jan 2, 2024
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.
Taking everything into account, AMPH scores 7 out of 10 in our fundamental rating. AMPH was compared to 204 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make AMPH a good candidate for value and growth investing.
For an up to date full fundamental analysis you can check the fundamental report of AMPH
Our Lois Navellier screen will find you more ideas suited for growth investing.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (4/22/2024, 7:00:00 PM)
After market: 40.17 0 (0%)40.17
+0.16 (+0.4%)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.